CoChat
Sign Up
Cited by 308

The DOI matches its Crossref record.

Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database

Rusch, Valerie W., Giroux, Dorothy, Kennedy, Catherine, Ruffini, Enrico, Cangir, Ayten K., Rice, David, Pass, Harvey, Asamura, Hisao, Waller, David, Edwards, John, Weder, Walter, Hoffmann, Hans, van Meerbeeck, Jan P.·2012·Journal of Thoracic Oncology
DOI 10.1097/jto.0b013e31826915f1
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/jto.0b013e31826915f1

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 44

  1. Rusch, 1995, A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group, Chest, 108, 1122, 10.1378/chest.108.4.1122 · DOI
  2. Goldstraw, 2007, Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours, J Thorac Oncol, 2, 706, 10.1097/JTO.0b013e31812f3c1a · DOI · Paper page
  3. Vogelzang, 2003, Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma, J Clin Oncol, 21, 2636, 10.1200/JCO.2003.11.136 · DOI · Paper page
  4. de Perrot, 2009, Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma, J Clin Oncol, 27, 1413, 10.1200/JCO.2008.17.5604 · DOI
  5. Bölükbas, 2011, Survival after trimodality therapy for malignant pleural mesothelioma: radical Pleurectomy, chemotherapy with Cisplatin/Pemetrexed and radiotherapy, Lung Cancer, 71, 75, 10.1016/j.lungcan.2009.08.019 · DOI
  6. Weder, 2007, Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma, Ann Oncol, 18, 1196, 10.1093/annonc/mdm093 · DOI
  7. Hasani, 2009, Outcome for patients with malignant pleural mesothelioma referred for trimodality therapy in Western Australia, J Thorac Oncol, 4, 1010, 10.1097/JTO.0b013e3181ae25bf · DOI
  8. Krug, 2009, Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma, J Clin Oncol, 27, 3007, 10.1200/JCO.2008.20.3943 · DOI
  9. Yamanaka, 2009, A feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation for malignant pleural mesothelioma, Jpn J Clin Oncol, 39, 186, 10.1093/jjco/hyn145 · DOI
  10. Richards, 2010, Proposed adjustments to pathologic staging of epithelial malignant pleural mesothelioma based on analysis of 354 cases, Cancer, 116, 1510, 10.1002/cncr.24886 · DOI
  11. Mineo, 2008, The value of occult disease in resection margin and lymph node after extrapleural pneumonectomy for malignant mesothelioma, Ann Thorac Surg, 85, 1740, 10.1016/j.athoracsur.2008.01.088 · DOI
  12. Flores, 2007, Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center, J Thorac Oncol, 2, 957, 10.1097/JTO.0b013e31815608d9 · DOI
  13. Yan, 2009, Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors, J Thorac Cardiovasc Surg, 138, 619, 10.1016/j.jtcvs.2008.12.045 · DOI
  14. Flores, 2008, The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: implications for revision of the American Joint Committee on Cancer staging system, J Thorac Cardiovasc Surg, 136, 605, 10.1016/j.jtcvs.2008.02.069 · DOI
  15. Cao, 2011, Staging of patients after extrapleural pneumonectomy for malignant pleural mesothelioma–institutional review and current update, Interact Cardiovasc Thorac Surg, 12, 754, 10.1510/icvts.2010.262972 · DOI
  16. de Perrot, 2007, Impact of lymph node metastasis on outcome after extrapleural pneumonectomy for malignant pleural mesothelioma, J Thorac Cardiovasc Surg, 133, 111, 10.1016/j.jtcvs.2006.06.044 · DOI
  17. Liu, 2010, Assessment of therapy responses and prediction of survival in malignant pleural mesothelioma through computer-aided volumetric measurement on computed tomography scans, J Thorac Oncol, 5, 879, 10.1097/JTO.0b013e3181dd0ef1 · DOI
  18. Plathow, 2008, Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT, Eur Radiol, 18, 1635, 10.1007/s00330-008-0918-9 · DOI
  19. Nowak, 2010, A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters, Clin Cancer Res, 16, 2409, 10.1158/1078-0432.CCR-09-2313 · DOI
  20. Ak, 2010, Three-dimensional evaluation of chemotherapy response in malignant pleural mesothelioma, Eur J Radiol, 74, 130, 10.1016/j.ejrad.2009.02.002 · DOI
  21. Frauenfelder, 2011, Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma?, Eur Respir J, 38, 162, 10.1183/09031936.00146110 · DOI
  22. Sensakovic, 2011, Computerized segmentation and measurement of malignant pleural mesothelioma, Med Phys, 38, 238, 10.1118/1.3525836 · DOI
  23. Nakas, 2010, Surgical assessment of malignant pleural mesothelioma: have we reached a critical stage?, Eur J Cardiothorac Surg, 37, 1457, 10.1016/j.ejcts.2009.12.039 · DOI
  24. Rusch, 1996, The importance of surgical staging in the treatment of malignant pleural mesothelioma, J Thorac Cardiovasc Surg, 111, 25, 10.1016/S0022-5223(96)70342-2 · DOI
  25. Rusch, 2001, A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma, J Thorac Cardiovasc Surg, 122, 788, 10.1067/mtc.2001.116560 · DOI
  26. Edwards, 2006, The pattern of lymph node involvement influences outcome after extrapleural pneumonectomy for malignant mesothelioma, J Thorac Cardiovasc Surg, 131, 981, 10.1016/j.jtcvs.2005.11.044 · DOI
  27. Weder, 2004, Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma, J Clin Oncol, 22, 3451, 10.1200/JCO.2004.10.071 · DOI
  28. Rea, 2007, Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results, Lung Cancer, 57, 89, 10.1016/j.lungcan.2007.02.004 · DOI
  29. Batirel, 2008, Trimodality treatment of malignant pleural mesothelioma, J Thorac Oncol, 3, 499, 10.1097/JTO.0b013e31816fca1b · DOI
  30. Van Schil, 2010, Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial, Eur Respir J, 36, 1362, 10.1183/09031936.00039510 · DOI
  31. Cao, 2010, A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma, J Thorac Oncol, 5, 1692, 10.1097/JTO.0b013e3181ed0489 · DOI
  32. Flores, 2008, Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients, J Thorac Cardiovasc Surg, 135, 6, 10.1016/j.jtcvs.2007.10.054 · DOI
  33. Martin-Ucar, 2007, Case-control study between extrapleural pneumonectomy and radical pleurectomy/decortication for pathological N2 malignant pleural mesothelioma, Eur J Cardiothorac Surg, 31, 70, 10.1016/j.ejcts.2007.01.064 · DOI
  34. Scherpereel, 2010, Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma, Eur Respir J, 35, 479, 10.1183/09031936.00063109 · DOI
  35. Yan, 2011, Improving survival results after surgical management of malignant pleural mesothelioma: an Australian institution experience, Ann Thorac Cardiovasc Surg, 17, 243, 10.5761/atcs.oa.10.01572 · DOI
  36. de Perrot, 2008, Risk factors for major complications after extrapleural pneumonectomy for malignant pleural mesothelioma, Ann Thorac Surg, 85, 1206, 10.1016/j.athoracsur.2007.11.065 · DOI
  37. Aigner, 2008, Outcome after extrapleural pneumonectomy for malignant pleural mesothelioma, Eur J Cardiothorac Surg, 34, 204, 10.1016/j.ejcts.2008.03.003 · DOI
  38. Schipper, 2008, Malignant pleural mesothelioma: surgical management in 285 patients, Ann Thorac Surg, 85, 64, 10.1016/j.athoracsur.2007.06.066 · DOI
  39. Rice, 2007, Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma, Ann Thorac Surg, 84, 92, 10.1016/j.athoracsur.2007.04.076 · DOI
  40. Nakas, 2008, Open lung-sparing surgery for malignant pleural mesothelioma: the benefits of a radical approach within multimodality therapy, Eur J Cardiothorac Surg, 34, 886, 10.1016/j.ejcts.2008.06.010 · DOI
  41. Luckraz, 2010, Three decades of experience in the surgical multi-modality management of pleural mesothelioma, Eur J Cardiothorac Surg, 37, 552, 10.1016/j.ejcts.2009.07.032 · DOI
  42. Sugarbaker, 2011, Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy, Eur J Cardiothorac Surg, 40, 298
  43. Treasure, 2011, Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study, Lancet Oncol, 12, 763, 10.1016/S1470-2045(11)70149-8 · DOI
  44. Weder, 2011, The MARS feasibility trial: conclusions not supported by data, Lancet Oncol, 12, 4, 10.1016/S1470-2045(11)70307-2 · DOI

Cited by

Sorted by citations

Metadata

Authors
Rusch, V. W., Giroux, D., Kennedy, C., Ruffini, E., Cangir, A. K., Rice, D., Pass, H., Asamura, H., Waller, D., Edwards, J., Weder, W., Hoffmann, H., & van Meerbeeck, J. P.
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2012-11
Volume
7
Issue
11
Pages
1631-1639
ISSN
1556-0864
DOI
10.1097/jto.0b013e31826915f1
Cited by
308
References
0
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review